<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 0-24875
NOTIFICATION OF LATE FILING
(Check One:) |X| Form 10-K |_| Form 11-K |_| Form 20-F |_| Form 10-Q
|_| Form N-SAR
For Period Ended: September 30, 2000
|_| Transition Report on Form 10-K |_| Transition Report on Form 10-Q
|_| Transition Report on Form 20-F |_| Transition Report on Form N-SAR
|_| Transition Report on Form 11-K
For the Transition Period Ended: ______________________________
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Full name of registrant: Bioenvision Inc.
Former name if applicable: Ascot Group Inc.
Address of principal executive office: One Rockefeller Plaza, Suite 1600, New
York, New York 10020
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
-1-
<PAGE>
|X| (a) The reasons described in reasonable detail in Part
III of this form could not be eliminated without
unreasonable effort or expense;
|X|
(b) The subject annual report, semi-annual report,
transition report on Form 10-K, 20-F, 11-K or Form
N-SAR, or portion thereof will be filed on or before
the 15th calendar day following the prescribed due
date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached, if
applicable. Inapplicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)
Bioenvision Inc. has worked diligently to complete its Annual Report on
Form 10-KSB; however, Bioenvision has been unable to complete the Form 10-KSB by
the required date without unreasonable effort and expense. The audit of
Bioenvision's financial statements is in the final stages of completion, however
Bioenvision's accountants have experienced delays in conducting the audit due to
the extensive due diligence process necessary because a large proportion of
Bioenvision's commercial operations are performed outside the United States,
largely in the United Kingdom. Bioenvision respectfully requests a fifteen day
extension, pursuant to Rule 12b-25 of the Securities Exchange Act of 1934, in
order to file its Annual Report on Form 10-KSB.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Andrew J. Cosentino (212) 835-6000
(Name) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registration was required to file such report(s) been filed? If the answer is
no, identify report(s).
|X| Yes |_| No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
|_| Yes |X| No
-2-
<PAGE>
If so: attach an explanation of the anticipated change, both
narratively and quantitatively and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
-3-
<PAGE>
BIOENVISION INC.
(Name of Registrant Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: September 28, 2000 By: /s/ Christopher B. Wood
---------------------------
Christopher B. Wood
Chairman and Chief Executive Officer
-4-
